GTG Genetic Technologies

GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

GTG Signs Precision Medicine Pilot with Australia’s Largest Private Hospital Network

MELBOURNE, Australia, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”) – a global leader in genomics-based tests in health, wellness and serious disease is pleased to announce a partnership with the Gold Coast Private Hospital (GCPH), a member of Healthscope, to establish a Precision Medicine Clinic at the hospital.

Highlights:

  • Partnership will be initiated with a 50-patient pilot study to establish workflow and patient reporting.
  • Pilot study will utilise geneType Multi-risk test combined with Pharmacogenomics (PGx) tests, providing a comprehensive wellness profile for GCPH patients.
  • Patient recruitment to commence immediately.
  • Positive outcomes could enable the rollout of additional Precision Medicine Clinics throughout the Healthscope network.
  • Gold Coast Private Hospital by Healthscope is a 336 bed, 22 theatre hospital and home to leading doctors and surgeons from around the world.
  • Healthscope is Australia's only national private hospital operation and healthcare provider with a network of 42 hospitals that service every state and territory with 19,000 employees.



According to the US Food and Drug Administration (FDA), Precision Medicine, also known as "personalised medicine" is an innovative approach to tailoring disease prevention and treatment that takes into account differences in people's genes, environments, and lifestyles. The goal of precision medicine is to target the right treatments to the right patients at the right time. Utilising GTG’s geneType Multi-test and PGx tests will be an important step in improving health outcomes for GCPH’s patients.

Research Manager for the Gold Coast private hospital, Michelle Ferrari Cestari, commented, “We have a clear vision for a Precision Medicine Clinic that focuses on preventative care, wellness and creating proactive patient pathways that lead to early detection, and better treatment of the common diseases.”



-END-

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M:

E:

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit

About Gold Coast Private Hospital by Healthscope

Gold Coast Private Hospital by Healthscope is a 336 bed and 22 theatre hospital is home to leading doctors and surgeons. The focus is on the patient with and expert team of surgeons, specialist doctors, dedicated nurses and other supporting health professionals ensuring holistic health care experience is the best it can be.

Offering the latest technology, and truly impressive state-of-the-art facilities, they attract leading doctors and surgeons from across the world. This, in turn, has meant that we are the Gold Coast hospital of choice for GPs, consultants and, of course, patients who quite rightly place a premium on their health and wellbeing

Healthscope is Australia's only national private hospital operation and healthcare provider with a network of 42 hospitals that service every state and territory. With over 19,000 people and provide work for nearly as many accredited medical practitioners. Our people are known for achieving exceptional clinical outcomes, transparent public reporting and positive patient feedback that leads the industry. No matter the role, every day the people make a difference to the lives of patients, their families and carers, and it is a privilege to be part of their care.

Photos accompanying this announcement are available at:



EN
27/09/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genetic Technologies

 PRESS RELEASE

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on October 2 MELBOURNE, Australia, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on October 2, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Genetic Technologies’ senior leadership who will share insight into the Company’s portfolio of genomics-based...

 PRESS RELEASE

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Pla...

Genetic Technologies Invited to Join Prestigious “CancerIQ” Online Platform - Provides Access to 45 Healthcare Systems and 250 Clinics MELBOURNE, Australia, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to announce the Company has negotiated a partnership agreement with Chicago-based CancerIQ. CancerIQ enables Healthcare Institutions and Clinics to support cancer prevention programs by supporting and simplifying the identification ...

 PRESS RELEASE

Genetic Technologies Announces Global Launch of geneType™ on Wholly Ow...

Genetic Technologies Announces Global Launch of geneType™ on Wholly Owned EasyDNA platform CHARLOTTE, N.C., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, is pleased to announce the global launch of the geneType™ Risk Assessment portfolio on our wholly owned EasyDNA platform currently selling in 42 countries, setting the stage for the potential significant expansion of the Company’s current A$7.5m annual revenues....

 PRESS RELEASE

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Sess...

Join Genetic Technology’s Exclusive Live Investor Webinar and Q&A Session on August 15 MELBOURNE, Australia, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG; NASDAQ:GENE, “Company”, “GTG”, or “Genetic Technologies”), a global leader in guideline-driven genomics-based tests in health, wellness and serious diseases, is pleased to invite investors to a webinar on August 15, 2024, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature some of Genetic Technologies Senior Executives, who will share insight into the Company’s portfolio of genomic...

 PRESS RELEASE

Genetic Technologies Strategic Restructure Driving USA Sales Growth

Genetic Technologies Strategic Restructure Driving USA Sales Growth CHARLOTTE, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease and the parent company of geneType™, has conducted an operations review and announces that it intends to transition to a capital light operations model – which is anticipated to result in an immediate material reduction in operating costs. This capital light operations model is intended to focus on sales growth (particul...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch